Goldman-Backed Biotech Attovia Raises $289 Million in US IPO

Attovia Therapeutics Inc. raised 289 million dollars in a US initial public offering that priced at the top of its marketed range. The company develops drugs focused on immune system diseases. Goldman Sachs backed the offering.

Next story